MD Anderson and Theraclone Sciences form OncoResponse
OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by MD Anderson Cancer Center and Theraclone Sciences. OncoResponse will use Theraclone’s I-STAR™ immune repertoire screening technology to identify therapeutic antibodies against novel targets. October 06, 2015